Penumbra, Inc. reported second quarter 2026 financial results with revenue of $390.0 million, a 14.9% increase year-over-year. Global thrombectomy revenue rose 12.5% to $259.0 million, while embolization and access revenue grew 20.0% to $131.1 million. The company achieved a gross profit margin of 67.9%, up 1.9 percentage points, and reported net income of $34.8 million. Operating expenses totaled $223.9 million, including $6.9 million in acquisition-related costs associated with its pending merger with Boston Scientific Corporation. Due to the pending acquisition, Penumbra did not provide full-year financial guidance or host a conference call. Penumbra is a medical device company specializing in thrombectomy technologies for treating ischemic stroke and other vascular conditions.